Review



pasw statistics (version 17  (SPSS Inc)


Bioz Verified Symbol SPSS Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    SPSS Inc pasw statistics (version 17
    Pasw Statistics (Version 17, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pasw+version+17/pmc03124413-223-5-9?v=SPSS+Inc
    Average 90 stars, based on 1 article reviews
    pasw statistics (version 17 - by Bioz Stars, 2026-07
    90/100 stars

    Images



    Similar Products

    pasw statistics (version 17  (SPSS Inc)
    90
    SPSS Inc pasw statistics (version 17
    Pasw Statistics (Version 17, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pasw+version+17/pmc03124413-223-5-9?v=SPSS+Inc
    Average 90 stars, based on 1 article reviews
    pasw statistics (version 17 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pasw statistics software version 17  (SPSS Inc)
    90
    SPSS Inc pasw statistics software version 17
    Pasw Statistics Software Version 17, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pasw+version+17/pmc02995473-97-7-12?v=SPSS+Inc
    Average 90 stars, based on 1 article reviews
    pasw statistics software version 17 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pasw version 17  (SPSS Inc)
    90
    SPSS Inc pasw version 17
    RUNX2 silencing reduces migration of metastatic MDA-MB-231 breast cancer cells . (A) Diminished expression of RUNX2 protein levels was observed by western blotting in lysates from MDA-MB-231 treated with siRUNX2. ( B ) Wound healing assay of MDA-MB-231 cells treated with siRUNX2 or a non-silencing RNA (AllStar Control) at five different time points. (C) Cell counts were performed to determine the number of cells migrating to the scratch zone after 24 h for MDA-MB-231 cells treated with siRUNX2 ( n = 180 cells) or non-silencing AllStar Control ( n = 242 cells). (D) Total percent closure was determined as a time-course after initiating the scratch. Control MDA-MB-231 cells transfected with AllStar Control (88%) achieved 29% percent closure, while cells treated with siRUNX2 (59%) exhibited reduced wound closure. Asterisk indicates statistical significance between siRUNX2 and control treatment ( P < 0.01 based on <t>ANCOVA</t> test). Error bars represent standard deviation.
    Pasw Version 17, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pasw+version+17/pmc03096982-69-2-8?v=SPSS+Inc
    Average 90 stars, based on 1 article reviews
    pasw version 17 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pasw software version 17 windows  (SPSS Inc)
    90
    SPSS Inc pasw software version 17 windows
    RUNX2 silencing reduces migration of metastatic MDA-MB-231 breast cancer cells . (A) Diminished expression of RUNX2 protein levels was observed by western blotting in lysates from MDA-MB-231 treated with siRUNX2. ( B ) Wound healing assay of MDA-MB-231 cells treated with siRUNX2 or a non-silencing RNA (AllStar Control) at five different time points. (C) Cell counts were performed to determine the number of cells migrating to the scratch zone after 24 h for MDA-MB-231 cells treated with siRUNX2 ( n = 180 cells) or non-silencing AllStar Control ( n = 242 cells). (D) Total percent closure was determined as a time-course after initiating the scratch. Control MDA-MB-231 cells transfected with AllStar Control (88%) achieved 29% percent closure, while cells treated with siRUNX2 (59%) exhibited reduced wound closure. Asterisk indicates statistical significance between siRUNX2 and control treatment ( P < 0.01 based on <t>ANCOVA</t> test). Error bars represent standard deviation.
    Pasw Software Version 17 Windows, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pasw+version+17/pmc03095026-77-22-28?v=SPSS+Inc
    Average 90 stars, based on 1 article reviews
    pasw software version 17 windows - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pasw statistics, version 17  (SPSS Inc)
    90
    SPSS Inc pasw statistics, version 17
    RUNX2 silencing reduces migration of metastatic MDA-MB-231 breast cancer cells . (A) Diminished expression of RUNX2 protein levels was observed by western blotting in lysates from MDA-MB-231 treated with siRUNX2. ( B ) Wound healing assay of MDA-MB-231 cells treated with siRUNX2 or a non-silencing RNA (AllStar Control) at five different time points. (C) Cell counts were performed to determine the number of cells migrating to the scratch zone after 24 h for MDA-MB-231 cells treated with siRUNX2 ( n = 180 cells) or non-silencing AllStar Control ( n = 242 cells). (D) Total percent closure was determined as a time-course after initiating the scratch. Control MDA-MB-231 cells transfected with AllStar Control (88%) achieved 29% percent closure, while cells treated with siRUNX2 (59%) exhibited reduced wound closure. Asterisk indicates statistical significance between siRUNX2 and control treatment ( P < 0.01 based on <t>ANCOVA</t> test). Error bars represent standard deviation.
    Pasw Statistics, Version 17, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pasw+version+17/pmc03199886-115-6-10?v=SPSS+Inc
    Average 90 stars, based on 1 article reviews
    pasw statistics, version 17 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pasw statistics 17, release version 17.0.2  (SPSS Inc)
    90
    SPSS Inc pasw statistics 17, release version 17.0.2
    RUNX2 silencing reduces migration of metastatic MDA-MB-231 breast cancer cells . (A) Diminished expression of RUNX2 protein levels was observed by western blotting in lysates from MDA-MB-231 treated with siRUNX2. ( B ) Wound healing assay of MDA-MB-231 cells treated with siRUNX2 or a non-silencing RNA (AllStar Control) at five different time points. (C) Cell counts were performed to determine the number of cells migrating to the scratch zone after 24 h for MDA-MB-231 cells treated with siRUNX2 ( n = 180 cells) or non-silencing AllStar Control ( n = 242 cells). (D) Total percent closure was determined as a time-course after initiating the scratch. Control MDA-MB-231 cells transfected with AllStar Control (88%) achieved 29% percent closure, while cells treated with siRUNX2 (59%) exhibited reduced wound closure. Asterisk indicates statistical significance between siRUNX2 and control treatment ( P < 0.01 based on <t>ANCOVA</t> test). Error bars represent standard deviation.
    Pasw Statistics 17, Release Version 17.0.2, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pasw+version+17/pmc03228659-142-51-54?v=SPSS+Inc
    Average 90 stars, based on 1 article reviews
    pasw statistics 17, release version 17.0.2 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pasw statistical software package version 17  (SPSS Inc)
    90
    SPSS Inc pasw statistical software package version 17
    RUNX2 silencing reduces migration of metastatic MDA-MB-231 breast cancer cells . (A) Diminished expression of RUNX2 protein levels was observed by western blotting in lysates from MDA-MB-231 treated with siRUNX2. ( B ) Wound healing assay of MDA-MB-231 cells treated with siRUNX2 or a non-silencing RNA (AllStar Control) at five different time points. (C) Cell counts were performed to determine the number of cells migrating to the scratch zone after 24 h for MDA-MB-231 cells treated with siRUNX2 ( n = 180 cells) or non-silencing AllStar Control ( n = 242 cells). (D) Total percent closure was determined as a time-course after initiating the scratch. Control MDA-MB-231 cells transfected with AllStar Control (88%) achieved 29% percent closure, while cells treated with siRUNX2 (59%) exhibited reduced wound closure. Asterisk indicates statistical significance between siRUNX2 and control treatment ( P < 0.01 based on <t>ANCOVA</t> test). Error bars represent standard deviation.
    Pasw Statistical Software Package Version 17, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pasw+version+17/pmc03493289-104-6-12?v=SPSS+Inc
    Average 90 stars, based on 1 article reviews
    pasw statistical software package version 17 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pasw version 17 package  (SPSS Inc)
    90
    SPSS Inc pasw version 17 package
    RUNX2 silencing reduces migration of metastatic MDA-MB-231 breast cancer cells . (A) Diminished expression of RUNX2 protein levels was observed by western blotting in lysates from MDA-MB-231 treated with siRUNX2. ( B ) Wound healing assay of MDA-MB-231 cells treated with siRUNX2 or a non-silencing RNA (AllStar Control) at five different time points. (C) Cell counts were performed to determine the number of cells migrating to the scratch zone after 24 h for MDA-MB-231 cells treated with siRUNX2 ( n = 180 cells) or non-silencing AllStar Control ( n = 242 cells). (D) Total percent closure was determined as a time-course after initiating the scratch. Control MDA-MB-231 cells transfected with AllStar Control (88%) achieved 29% percent closure, while cells treated with siRUNX2 (59%) exhibited reduced wound closure. Asterisk indicates statistical significance between siRUNX2 and control treatment ( P < 0.01 based on <t>ANCOVA</t> test). Error bars represent standard deviation.
    Pasw Version 17 Package, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pasw+version+17/pmc03500141-114-7-11?v=SPSS+Inc
    Average 90 stars, based on 1 article reviews
    pasw version 17 package - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    RUNX2 silencing reduces migration of metastatic MDA-MB-231 breast cancer cells . (A) Diminished expression of RUNX2 protein levels was observed by western blotting in lysates from MDA-MB-231 treated with siRUNX2. ( B ) Wound healing assay of MDA-MB-231 cells treated with siRUNX2 or a non-silencing RNA (AllStar Control) at five different time points. (C) Cell counts were performed to determine the number of cells migrating to the scratch zone after 24 h for MDA-MB-231 cells treated with siRUNX2 ( n = 180 cells) or non-silencing AllStar Control ( n = 242 cells). (D) Total percent closure was determined as a time-course after initiating the scratch. Control MDA-MB-231 cells transfected with AllStar Control (88%) achieved 29% percent closure, while cells treated with siRUNX2 (59%) exhibited reduced wound closure. Asterisk indicates statistical significance between siRUNX2 and control treatment ( P < 0.01 based on ANCOVA test). Error bars represent standard deviation.

    Journal: Breast Cancer Research : BCR

    Article Title: Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility

    doi: 10.1186/bcr2762

    Figure Lengend Snippet: RUNX2 silencing reduces migration of metastatic MDA-MB-231 breast cancer cells . (A) Diminished expression of RUNX2 protein levels was observed by western blotting in lysates from MDA-MB-231 treated with siRUNX2. ( B ) Wound healing assay of MDA-MB-231 cells treated with siRUNX2 or a non-silencing RNA (AllStar Control) at five different time points. (C) Cell counts were performed to determine the number of cells migrating to the scratch zone after 24 h for MDA-MB-231 cells treated with siRUNX2 ( n = 180 cells) or non-silencing AllStar Control ( n = 242 cells). (D) Total percent closure was determined as a time-course after initiating the scratch. Control MDA-MB-231 cells transfected with AllStar Control (88%) achieved 29% percent closure, while cells treated with siRUNX2 (59%) exhibited reduced wound closure. Asterisk indicates statistical significance between siRUNX2 and control treatment ( P < 0.01 based on ANCOVA test). Error bars represent standard deviation.

    Article Snippet: Analysis of co-variance (ANCOVA) tests (PASW version 17, SPSS Inc., Chicago, IL, USA) were used to statistically assess the significance of differences between either siRUNX2 group or RUNX2 overexpression group vs control in the time course migration assays.

    Techniques: Migration, Expressing, Western Blot, Wound Healing Assay, Transfection, Standard Deviation

    RUNX2 expression increases cell migration in non-metastatic MCF7 breast cancer cells . (A) Western blot analysis using a RUNX2 antibody and/or c-Myc epitope tag in MCF7 cells transfected with a Myc-RUNX2 expression vector. Levels of β-actin were used as a control for protein loading) (B) Images from a wound healing assay with MCF7 cells transfected with empty expression vector (pcDNA3 control) or a plasmid expressing Myc-RUNX2 at various time points (in hours). (C) Quantification of total percent closure of control MCF7 cells (pcDNA3; 34%) and Myc-RUNX2 expressing MCF7 cells (41%) revealed that RUNX2 expressing increases cell motility. Asterisk indicates statistical significance between Myc-RUNX2 and control treatment ( P < 0.05 based on ANCOVA test). Error bars represent standard deviation.

    Journal: Breast Cancer Research : BCR

    Article Title: Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility

    doi: 10.1186/bcr2762

    Figure Lengend Snippet: RUNX2 expression increases cell migration in non-metastatic MCF7 breast cancer cells . (A) Western blot analysis using a RUNX2 antibody and/or c-Myc epitope tag in MCF7 cells transfected with a Myc-RUNX2 expression vector. Levels of β-actin were used as a control for protein loading) (B) Images from a wound healing assay with MCF7 cells transfected with empty expression vector (pcDNA3 control) or a plasmid expressing Myc-RUNX2 at various time points (in hours). (C) Quantification of total percent closure of control MCF7 cells (pcDNA3; 34%) and Myc-RUNX2 expressing MCF7 cells (41%) revealed that RUNX2 expressing increases cell motility. Asterisk indicates statistical significance between Myc-RUNX2 and control treatment ( P < 0.05 based on ANCOVA test). Error bars represent standard deviation.

    Article Snippet: Analysis of co-variance (ANCOVA) tests (PASW version 17, SPSS Inc., Chicago, IL, USA) were used to statistically assess the significance of differences between either siRUNX2 group or RUNX2 overexpression group vs control in the time course migration assays.

    Techniques: Expressing, Migration, Western Blot, Transfection, Plasmid Preparation, Wound Healing Assay, Standard Deviation